INOVIO Pharmaceuticals

New Capabilities

Developer and license holder for Voceryq

Adults with recurrent respiratory papillomatosis (RRP) have had one treatment: surgery to shave HPV-grown warts off the vocal cords and airway, often several times a year. On October 30, 2026, the Food and Drug Administration granted accelerated approval to Voceryq, an injected DNA-based immunotherapy meant to reduce how often those operations are needed.

Updated 1 hour ago